Supporting Shared Decision Making in CLL
No Patient Like Me
Over the past decade, significant progress has been made with chronic lymphocytic leukemia (CLL) treatment options. But while science continues to evolve, one aspect remains constant: every person’s experience of living with CLL is unique.
Each individual has their own priorities, concerns and goals. And when it comes to care, those personal factors matter. Yet, even today, delivering patient centred care remains complex. Physicians must balance clinical evidence with each patient’s personal priorities, values and lived experiences, while many patients find it difficult to express what matters most during treatment discussions and shared decision-making.
3 out of 4 people living with CLL prefer an active or shared role in decision-making, however, only 1 in 5 feel that they have one.1
Shared decision-making allows healthcare professionals and patients to work together to understand treatment options and individual priorities. By considering each patient’s individual profile, needs, goals, and lifestyle, their CLL treatment discussions can support more individualized, patient centered care.
Meaningful conversations start with understanding the patient in a holistic way beyond the disease and considering individual preferences before making decisions.
That’s why we’ve partnered with patient advocacy group, CLL Advocates Network, to create No Patient Like Me, a program that aims to support holistic treatment conversations and informed decisions. Through patient stories and practical resources, the program helps to ensure that individual needs, goals, and preferences remain part of the conversation in CLL care.
Putting patient priorities at the center
Hear directly how CLL patients navigated their conversations about CLL treatment with their doctors and ensured their voice was heard.
Understanding patient priorities is key in CLL care
Listen to a hematologist discuss the importance of patient-centered care in CLL and why understanding each patient’s priorities is essential when making CLL treatment decisions.